New study uses PET scans to see how kidney cancer drug changes key protein

NCT ID NCT07179770

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This early-phase study is looking at how the drug belzutifan affects a protein called CAIX in people with advanced clear cell kidney cancer. Researchers will use a special PET scan before and after four weeks of belzutifan treatment to measure changes in CAIX levels. The goal is to gather information that could help design better combination treatments in the future. The study involves 12 participants and is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
belzutifan (Welireg) and 89Zr-DFO-girentuximab (TLX250-CDx)
What this could lead to
If successful, this study could show how belzutifan affects CAIX levels, paving the way for more effective combination therapies for advanced kidney cancer.
What could go wrong
This is a very small, early-phase study with only 12 participants, so results may not apply broadly. The imaging technique is experimental, and the main goal is to gather information, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma Clear-cell metastatic renal cell carcinoma nonpapillary renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.